Product logins

Find logins to all Clarivate products below.


Moira Ringo

Director, Consulting

Moira comes to Clarivate with over 20 years of experience in healthcare industry and consulting, and focusses primarily on commercial strategy and market access. Moira began her career in GSK Research and Development after witnessing first-hand the power of medicine for a family member with cancer. At GSK she contributed to clinical development of over 20 assets, including the second approved personalized therapy for oncology. As she observed market access having an increasing role on product uptake, she transitioned to a role optimizing product strategy for newly launched and mature products at GSK, including supporting the launch of the first gene therapy for a rare disease.
Her consulting roles span US and global clinical, market access, and HEOR evidence strategy for advanced oncolytics, diagnostics, medical devices, and cell and gene therapies. She has developed robust channel, product, and market access strategies for the US market. Moira is passionate about uniting diverse client and consulting teams around the common goal of bringing science and technology to patients who need it.
Moira holds a PhD in chemistry from the University of Michigan and an MBA from the Duke Fuqua School of Business with a certificate in health sector management.


arrow_forward
Get in touch with Moira

Related resources

应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
Relacorilant:当证据满足既定证据标准时 Relacorilant:当证据满足既定证据标准时
Blog February 24, 2026
Relacorilant:当证据满足既定证据标准时
FDA 临床试验 市场准入 最值得关注的药物 真实世界数据 美国市场 药政法规
Tolebrutinib:当安全性隐忧掩盖疗效信号 Tolebrutinib:当安全性隐忧掩盖疗效信号
Blog February 24, 2026
Tolebrutinib:当安全性隐忧掩盖疗效信号
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规 药物安全